TABLE 7Multivariate HRs and performance measures for all cohorts based on multiple imputed data

CharacteristicOHTS-EGPS (development set)Rotterdam (validation set)Moorfields (validation set)Dunfermline (validation set)Nottingham (validation set)
n/Na154/112328/39344/29828/1885/159
Baseline predictor, HR (95% CI)
 Age (decade)1.26 (1.06 to 1.50)1.44 (0.95 to 2.18)1.20 (0.86 to 1.68)0.72 (0.48 to 1.08)1.23 (0.48 to 3.15)
 IOP (mmHg)1.09 (1.03 to 1.17)1.15 (1.04 to 1.27)1.07 (0.99 to 1.17)1.01 (0.92 to 1.11)0.94 (0.71 to 1.24)
 CCT (per 40 μm thinner)2.04 (1.70 to 2.45)1.31 (0.79 to 2.17)2.76 (1.44 to 5.26)Excluded1.62 (0.46 to 5.65)
 VCD ratio (per 0.1 larger)1.19 (1.09 to 1.31)1.52 (1.19 to 1.94)1.15 (0.90 to 1.47)1.36 (1.07 to 1.72)1.34 (0.76 to 2.37)
 PSD (per 0.2 dB greater)1.13 (1.04 to 1.24)1.15 (0.95 to 1.40)1.05 (0.96 to 1.15)1.06 (0.96 to 1.16)1.02 (0.94 to 1.11)
Performance measure
c-index0.74 (0.70 to 0.78)0.83 (0.75 to 0.91)0.69 (0.59 to 0.78)0.72 (0.63 to 0.82)0.70 (0.39 to 1.00)
 Calibration slopeNE1.09 (0.72 to 1.45)0.59 (0.19 to 0.99)0.21 (−0.33 to 0.74)0.24 (−0.17 to 0.65)
 Calibration χ27.32NENENENE

NE, not estimated.

a

n is the number of OAG cases and N is the total number of patients.

From: 4, Risk prediction tools for development of open-angle glaucoma

Cover of Surveillance for Ocular Hypertension: An Evidence Synthesis and Economic Evaluation
Surveillance for Ocular Hypertension: An Evidence Synthesis and Economic Evaluation.
Health Technology Assessment, No. 16.29.
Burr JM, Botello-Pinzon P, Takwoingi Y, et al.
Southampton (UK): NIHR Journals Library; 2012 Jun.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.